KANCERA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.412 SEK | -2.49% |
|
-4.98% | -68.93% |
| 23/02 | Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 23/02 | Kancera AB Signs A License Agreement with the University of Newcastle | CI |
| Sales 2023 | 1.03M 94.61K 7.89M | Sales 2024 * | - | Capitalization | 171M 15.64M 1.3B |
|---|---|---|---|---|---|
| Net income 2023 | -64M -5.85M -488M | Net income 2024 * | -81M -7.4M -617M | EV / Sales 2023 | 358 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-9.28
x | P/E ratio 2024 * |
-2.02
x | Employees | 3 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 37.38% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.49% | ||
| 1 week | -4.98% | ||
| Current month | -17.52% | ||
| 1 month | -17.62% | ||
| 3 months | -66.70% | ||
| 6 months | -61.47% | ||
| Current year | -68.93% |
1 week
1.36
1.55
1 month
1.361.97
Current year
1.364.70
1 year
1.366.77
3 years
1.3614.42
5 years
1.3643.30
10 years
1.36100.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 01/22/01 |
| Director of Finance/CFO | 75 | - | |
Martin Norin
COO | Chief Operating Officer | 65 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 05/10/05 | |
| Director/Board Member | 66 | 01/16/01 | |
Håkan Mellstedt
FOU | Founder | 82 | 28/10/28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.412 | -2.49% | 234,632 |
| 25/24/25 | 1.448 | -1.36% | 388,097 |
| 24/24/24 | 1.468 | -1.87% | 362,923 |
| 23/24/23 | 1.496 | -0.27% | 277,239 |
| 22/24/22 | 1.5 | +0.94% | 249,994 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotes
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Calendar
17/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -68.93% | 15.61M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KAN Stock
